Diagnosis and management of primary aldosteronism

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 15, Issue 4, 2008, Pages 332-338

  Boscaro, Marco ^a   Ronconi, Vanessa ^a   Turchi, Federica ^a   Giacchetti, Gilberta ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Adrenal venous sampling; Mineralocorticoid receptor antagonists; Primary aldosteronism; Screening tests

Indexed keywords

ALDOSTERONE; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANRENOATE POTASSIUM; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FLUDROCORTISONE; MINERALOCORTICOID ANTAGONIST; RENIN; SODIUM CHLORIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; ALDOSTERONE ANTAGONIST; MINERALOCORTICOID RECEPTOR;

ADENOMA; ADRENAL GLAND; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; BLOOD SAMPLING; CARDIOVASCULAR SYSTEM; COMPUTER ASSISTED TOMOGRAPHY; GLUCOSE METABOLISM; GYNECOMASTIA; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; REVIEW; SALT LOADING; SCREENING; SEXUAL DYSFUNCTION; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX TUMOR; DIFFERENTIAL DIAGNOSIS; DRUG ANTAGONISM; HYPERALDOSTERONISM; HYPOKALEMIA; METABOLISM;

ADRENAL CORTEX NEOPLASMS; ADRENAL GLANDS; ADRENOCORTICAL ADENOMA; ALDOSTERONE ANTAGONISTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; RECEPTORS, MINERALOCORTICOID;

EID: 55249126190     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283060a40     Document Type: Review

References (49)

1. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007; 66:607-618. This recent review summarizes the main clinical aspects regarding primary aldosteronism from the prevalence to the diagnosis and treatment. In particular, the author underlines the renewed interest for primary aldosteronism and suggests a practical management of this disease.
2. Lim PO, MacDonald TM. Primary aldosteronism, diagnosed by the aldosterone to renin ratio, is a common cause of hypertension. Clin Endocrinol 2003; 59:427-430.
3. Hood S, Cannon J, Foo R, Brown M. Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing. Clin Med 2005; 5:55-60.
4. Rossi GP, Bernini G, Caliumi C, et al., for the PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. The Journal of The American College of Cardiology 2006; 48:2293-2300.
5. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045-1050.
6. Milliez P, Girerd X, Plouin PF, et al. Evidence of an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248.
7. Giacchetti G, Ronconi V, Turchi F, et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007; 25:177-186. This long-term follow-up study demonstrates that treatment of aldosterone excess induces not only the improvement in blood pressure control but also the regression in cardiac and metabolic complications, indicating aldosterone as the main determinant of such alterations.
8. Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005; 16:104-107.
9. Sealey JE, Gordon RD, Mantero F. Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol Metab 2005; 16:86-91.
10. Montori VM, Young WF Jr. Use of plasma aldosterone concentration-toplasma renin activity ratio as a screening test for primary aldosteronism: a systematic review of the literature. Endocrinol Metab Clin North Am 2002; 31:619-632.
11. Giacchetti G, Ronconi V, Lucarelli G, et al. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 2006; 24:737-745.
12. Mulatero P, Dluhy RG, Giacchetti G, et al. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab 2005; 16:114-119.
13. Umpierrez GE, Cantey P, Smiley D, et al. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 2007; 30:1699-1703.
14. Lim PO, Dow E, Brennan G, et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14:311-315.
15. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40:897-902.
16. Mosso L, Carvajal C, González A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42:161-165.
17. Giacchetti G, Mulatero P, Mantero F, et al. Primary aldosteronism, a major form of low renin hypertension: from screening to diagnosis. Trends Endocrinol Metab 2008; 19:104-108. This study represents a statement document on screening, confirmatory tests and subtype differentiation of primary aldosteronism, derived from the Second International Workshop on Endocrine Hypertension held in Rome 22nd-23rd June 2007.
18. Kem DC, Weinberger MH, Mayes DM, Nugent CA. Saline suppression of plasma aldosterone in hypertension. Arch Intern Med 1971; 128:380-386.
19. Holland OB, Brown H, Kuhnert L, et al. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984; 6:717-723.
20. Mulatero P, Milan A, Fallo F, et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 1984; 91:2618-2623.
21. Rossi GP, Belfiore A, Bernini G, et al., PAPY Study Investigators. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens 2007; 25:1433-1442. This prospective multicenter study shows that the isotonic saline infusion test is well tolerated and specific for confirming primary aldosteronism and suggests the best aldosterone cut-off value for the diagnosis.
22. Schirpenbach C, Seiler L, Maser-Gluth C, et al. Confirmatory testing in normokalaemic primary aldosteronism: the value of the saline infusion test and urinary aldosterone metabolites. Eur J Endocrinol 2006; 154:865-873.
23. Connell J, Fraser R. Primary aldosteronism. In: Wass J, Shalet S, editors. The Oxford textbook of endocrinology and diabetes. Oxford: Oxford University Press; 2002. pp. 791-799.
24. Stowasser M, Gordon RD. Primary aldosteronism - careful investigation is essential and rewarding. Mol Cell Endocrinol 2004; 217:33-39.
25. Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 2001; 37:1440-1443.
26. Castro OL, Yu X, Kem DC. Diagnostic value of the postcaptopril test in primary aldosteronism. Hypertension 2002; 39:935-938.
27. Rossi GP, Belfiore A, Bernini G, et al., PAPY Study Investigators. Comparison of the captopril and the saline infusion test for excluding aldosteroneproducing adenoma. Hypertension 2007; 50:424-431.
28. Mulatero P, Bertello C, Garrone C, et al. Captopril test can give misleading results in patients with suspect primary aldosteronism [letter to the editor]. Hypertension 2007; 50:e26-e27.
29. Hambling C, Jung RT, Gunn A, et al. Re-evaluation of the captopril test for the diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxf) 1992; 36:499-503.
30. Weinberger MH, Grim CE, Hollifield JW, et al. Primary aldosteronism: diagnosis, localization,and treatment. Ann Intern Med 1979; 90:386-395.
31. Magill SB, Raff H, Shaker JL, et al. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab 2001; 86:1066-1071.
32. Harper R, Ferrett CG, McKnight JA, et al. Accuracy of CT scanning and adrenal vein sampling in the preoperative localization of aldosterone-secreting adrenal adenomas. Q J Med 1999; 92:643-650.
33. Vetter H, Fischer M, Galanski M, et al. Primary aldosteronism: diagnosis and noninvasive lateralization procedures. Cardiology 1985; 72 (Suppl 1):57-63.
34. Mansoor GA, Malchoff CD, Arici MH, et al. Unilateral adrenal hyperplasia causing primary aldosteronism: limitation of I-131 norcholesterol scanning. Am J Hypertens 2002; 15:459-464.
35. Gross MD, Shapiro B, Freitas JE. Limited significance of asymmetric adrenal visualisation on dexamethasone suppression scintigraphy. J Nucl Med 1985; 26:43-48.
36. Doppman JL, Gill JR Jr. Hyperaldosteronism: sampling the adrenal veins. Radiology 1996; 198:309-312.
37. Phillips JL, Walther MM, Pezzullo JC, et al. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosteroneproducing adrenal adenoma. J Clin Endocrinol Metab 2000; 85:4526-4533.
38. Young WF Jr, Stanson AW, Grant CS, et al. Primary aldosteronism: adrenal venous sampling. Surgery 1996; 120:913-919.
39. Loh KC, Koay ES, Khaw MC, et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85:2854-2859.
40. Mulatero P. Diagnosis of surgically-treatable forms of primary aldosteronism. Curr Hypertens Rev 2005; 1:259-266.
41. Mulatero P, Bertello C, Rossato D, et al. Roles of clinical criteria. CT scan and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. Clin Endocrinol Metab 2008; 93:1366-1371.
42. Rossi GP. New concepts in adrenal vein sampling for aldosterone in the diagnosis of primary aldosteronism. Curr Hypertens Rep 2007; 9:90-97.
43. Rossi GP, Ganzaroli C, Miotto D, et al. Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. J Hypertens 2006; 24:371-379.
44. Auchus RJ, Chandler DW, Singeetham S, et al. Measurement of 18-hydroxycorticosterone during adrenal vein sampling for primary aldosteronism. J Clin Endocrinol Metab 2007; 92:2648-2651.
45. Mengozzi G, Rossato D, Bertello C, et al. Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism. Clin Chem 2007; 53:1968-1971. The authors propose intraoperative rapid cortisol assay for improving the success rate of AVS, which is the gold standard test for subtype diagnosis of primary aldosteronism. This study shows indeed, that this new method is safe, reproducible, simple to perform and cost-effective.
46. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin- aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005; 6:120-126.
47. Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295:2638-2645.
48. Rossi GP, Sechi LA, Giacchetti G, et al. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008; 19:88-90.
49. Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168:80-85. This prospective study demonstrates a greater prevalence of cardiovascular diseases in primary aldosteronism than in essential hypertension. In addition, the different rate of cardiovascular events is reversed by removing the effects of aldosterone excess with either medical or surgical treatment.